Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qiagen ( (QGEN) ) has provided an announcement.
QIAGEN N.V. announced a significant managerial transaction involving the sale of shares by Roland Sackers, a member of the managing body. The transaction, which took place on the NYSE, involved the sale of shares valued at approximately $910,286.32, representing about 15% of Sackers’ overall holdings. This move could have implications for the company’s stock performance and investor sentiment, reflecting a notable shift in the personal holdings of a key executive.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples, with a market focus on improving healthcare outcomes.
Average Trading Volume: 1,463,714
Technical Sentiment Signal: Buy
Current Market Cap: $10.69B
For an in-depth examination of QGEN stock, go to TipRanks’ Overview page.